Blair Hannah A
Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand.
Drugs. 2025 Jan;85(1):97-101. doi: 10.1007/s40265-024-02125-1. Epub 2024 Dec 20.
Xeligekimab (Jinlixi) is a recombinant human interleukin (IL)-17A-neutralizing immunoglobulin (Ig)G4 monoclonal antibody being developed by Genrix (Shanghai) Biopharmaceutical for the treatment of plaque psoriasis, axial spondyloarthritis and lupus nephritis. Xeligekimab binds to IL-17A and blocks its interaction with the IL-17A receptor, thereby inhibiting the release of C-X-C motif chemokine ligand 1 and IL-6. On 27 August 2024, xeligekimab received approval in China for the treatment of adult patients with moderate to severe plaque psoriasis who are candidates for systemic therapy or phototherapy. Xeligekimab is under regulatory review in China for the treatment of axial spondyloarthritis and is undergoing phase II development for the treatment of lupus nephritis. This article summarizes the milestones in the development of xeligekimab leading to this first approval for plaque psoriasis.
希立奇单抗（金礼西）是健适（上海）生物制药公司正在开发的一种重组人白细胞介素（IL）-17A中和免疫球蛋白（Ig）G4单克隆抗体，用于治疗斑块状银屑病、强直性脊柱炎和狼疮性肾炎。希立奇单抗与IL-17A结合并阻断其与IL-17A受体的相互作用，从而抑制C-X-C基序趋化因子配体1和IL-6的释放。2024年8月27日，希立奇单抗在中国获批用于治疗适合全身治疗或光疗的中度至重度斑块状银屑病成人患者。希立奇单抗在中国正接受强直性脊柱炎治疗的监管审查，并且正在进行狼疮性肾炎治疗的II期开发。本文总结了希立奇单抗开发过程中促成其首次获批用于斑块状银屑病的各个关键节点。
